Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

2020 Sees Sharp Rise In EU New Drug Approvals

Products Include COVID-19 Vaccine & Remdesivir, Plus Three Gene Therapies

Executive Summary

The number of new drugs containing new active substances approved in the EU rose significantly in 2020, underpinned by a strong showing for orphan-designated products and a string of novel medicines for cancer and infectious diseases. Notable among the new clutch of approvals was the first ever COVID-19 vaccine, Pfizer/BioNTech's Comirnaty.

You may also be interested in...



US And EU Approvals In First Half 2021 Underscore US-First Orientation Of Novel Drug Development

Close to 90% of the FDA’s 2021 first half novel approvals were cleared in the US before Europe, while the EU’s EMA acted first on only 15% of its first half marketing authorizations for new active substances. Exclusive Pink Sheet analysis explores use of expedited review schemes, special pathways and other comparative trends.

UK Venture Plans ‘Smart’ Randomized Trials To Speed Access To New Drugs

A newly launched UK venture is planning to use smart randomized clinical trial design in collaboration with industry, patient, academic and clinical partners to develop better treatments for a range of life-threatening diseases.

Australian Regulator Proposes Fee Increase To Offset Rising Costs

A growing role in dealing with medicines shortages, COVID-19-related pressures and the costs of relocating to new premises are among the factors behind the TGA’s proposal to raise the fees it charges pharma firms for its regulatory services.

Topics

Related Companies

UsernamePublicRestriction

Register

PS143625

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel